Experienced in Migraine

Dr. Mark S. Adams

Internal Medicine
1406 W 5th St, Suite 201, 
London, KY 
Experienced in Migraine
1406 W 5th St, Suite 201, 
London, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Adams is a primary care provider, practicing in Internal Medicine in London, Kentucky. Dr. Adams is rated as an Experienced provider by MediFind in the treatment of Migraine. His top areas of expertise are Migraine, Severe Acute Respiratory Syndrome (SARS), and Pneumonia.

His clinical research consists of participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 3 clinical trials in the study of Migraine.

Specialties
Internal Medicine
Licenses
Internal Medicine in KY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

1406 W 5th St, Suite 201, London, KY 40741

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Enrollment Status: Terminated
Publish Date: December 20, 2023
Intervention Type: Drug, Device
Study Drug: INO-4800
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects
A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects
Enrollment Status: Completed
Publish Date: April 10, 2023
Intervention Type: Biological, Other
Study Phase: Phase 1/Phase 2
BAT3221032: A Randomized, Controlled Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects
BAT3221032: A Randomized, Controlled Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects
Enrollment Status: Completed
Publish Date: December 16, 2022
Intervention Type: Other
Study Phase: Not Applicable
CSD201301: An In-Clinic Confinement Study to Assess Elements of Abuse Liability for Four P13 Nicotine Pouches
CSD201301: An In-Clinic Confinement Study to Assess Elements of Abuse Liability for Four P13 Nicotine Pouches
Enrollment Status: Completed
Publish Date: June 29, 2022
Intervention Type: Other
Study Phase: Not Applicable
Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Bris10 (A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccines
Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Bris10 (A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccines
Enrollment Status: Completed
Publish Date: March 04, 2022
Intervention Type: Other, Biological
Study Phase: Phase 1
A Randomized, Multi-Center, Open-Label, Parallel-Cohort Study to Characterize Product Use in Smokers Switching From Combustible Cigarettes to a RELX Electronic Nicotine Delivery System (ENDS)
A Randomized, Multi-Center, Open-Label, Parallel-Cohort Study to Characterize Product Use in Smokers Switching From Combustible Cigarettes to a RELX Electronic Nicotine Delivery System (ENDS)
Enrollment Status: Completed
Publish Date: July 22, 2021
Intervention Type: Other
Study Phase: Not Applicable
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Vaccination Strategies With Stockpiled Inactivated Monovalent Influenza A(H5) Vaccines Administered Intramuscularly With Either AS03 or MF59® as Adjuvant
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Vaccination Strategies With Stockpiled Inactivated Monovalent Influenza A(H5) Vaccines Administered Intramuscularly With Either AS03 or MF59® as Adjuvant
Enrollment Status: Completed
Publish Date: July 14, 2020
Intervention Type: Biological
Study Phase: Phase 2
CSD190103: An Unblinded, Randomized, Multi-site, Two-way Crossover Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products A19010-W and B19010-F in Healthy Adult Snus Consumers.
CSD190103: An Unblinded, Randomized, Multi-site, Two-way Crossover Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products A19010-W and B19010-F in Healthy Adult Snus Consumers.
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Other
Study Phase: Not Applicable
CSD190102: An Unblinded, Randomized, Multi-site, Two-way Crossover Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products A19010-R and B19010-O in Healthy Adult Snus Consumers.
CSD190102: An Unblinded, Randomized, Multi-site, Two-way Crossover Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products A19010-R and B19010-O in Healthy Adult Snus Consumers.
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Other
Study Phase: Not Applicable
CSD190101: An Unblinded, Randomized, Multi-site, Two-way Crossover Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products A19010-F and B19010-F in Healthy Adult Snus Consumers.
CSD190101: An Unblinded, Randomized, Multi-site, Two-way Crossover Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products A19010-F and B19010-F in Healthy Adult Snus Consumers.
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Other
Study Phase: Not Applicable
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
Open-Label, Multicenter Study Evaluating the Safety and Efficacy of the Nicotine Replacement Therapy Chrono Quit Smoking Solution (CQSS2) System (21mg) Compared to the NicoDerm® CQ® Patch (21mg) for Smoking Cessation in Treatment Seeking Subjects
Open-Label, Multicenter Study Evaluating the Safety and Efficacy of the Nicotine Replacement Therapy Chrono Quit Smoking Solution (CQSS2) System (21mg) Compared to the NicoDerm® CQ® Patch (21mg) for Smoking Cessation in Treatment Seeking Subjects
Enrollment Status: Completed
Publish Date: December 04, 2017
Intervention Type: Drug
Study Phase: Phase 2
CSD170304: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Electronic and Combustible Cigarettes
CSD170304: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Electronic and Combustible Cigarettes
Enrollment Status: Completed
Publish Date: November 14, 2017
Intervention Type: Other
Study Phase: Not Applicable
View 20 Less Clinical Trials
Similar Doctors
Experienced in Migraine
Dr. Aletia G. Farmer
Internal Medicine
Experienced in Migraine
Dr. Aletia G. Farmer
Internal Medicine

Family Practice Associates Of Lexington PSC

Brannon - 615 East Brannon Rd, 
Nicholasville, KY 
 (58.4 miles away)
859-278-5007
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aletia Farmer is a primary care provider, practicing in Internal Medicine in Nicholasville, Kentucky. Dr. Farmer is rated as an Advanced provider by MediFind in the treatment of Migraine. Her top areas of expertise are Bronchitis, Type 2 Diabetes (T2D), Hypothyroidism, and Glucocorticoid-Remediable Aldosteronism.

Experienced in Migraine
Dr. Amanda R. Foxx
Pediatrics | Internal Medicine
Experienced in Migraine
Dr. Amanda R. Foxx
Pediatrics | Internal Medicine

Family Practice Associates Of Lexington PSC

Brannon - 615 East Brannon Rd, 
Nicholasville, KY 
 (58.4 miles away)
859-278-5007
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amanda Foxx is a primary care provider, practicing in Pediatrics and Internal Medicine in Nicholasville, Kentucky. Dr. Foxx is rated as an Advanced provider by MediFind in the treatment of Migraine. Her top areas of expertise are Tracheitis, High Cholesterol, Folate Deficiency, and Vitamin B12 Deficiency Anemia.

Experienced in Migraine
Dr. Mehul A. Suthar
Internal Medicine
Experienced in Migraine
Dr. Mehul A. Suthar
Internal Medicine

Baptist Health Medical Group Inc

801 Eastern Bypass, 
Richmond, KY 
 (43.9 miles away)
859-623-3131
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mehul Suthar is a primary care provider, practicing in Internal Medicine in Richmond, Kentucky. Dr. Suthar is rated as an Advanced provider by MediFind in the treatment of Migraine. His top areas of expertise are Lung Metastases, End-Stage Renal Disease (ESRD), Type 2 Diabetes (T2D), and Malnutrition. Dr. Suthar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Adams's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile